Vpliv pooperativne radioterapije pri multimodalnem zdravljenju lokalno napredovalega raka dojke

We retrospectively analyzed the data from 55 patients treated for noninflammatory locally advanced breast cancer (LABC) with neoadjuvant chemotherapy and surgery with or without radiotherapy. The mean follow-up was 55 months. The purpose was to evaluate and compare the impact of postoperative radiotherapy, whether it was indicated on the basis of clinical stage at presentation of the disease or on downstaged pathological disease after initial chemotherapy. The 3-year overall survival (OS) was 74%, disease-free survival (DFS) 73% and relapse-free survival (RFS) 87%. The OS and DFS benefit was seen in those receiving radiation, with a mean OS of 89 months vs. 68 months (p=0.029) and mean DFS of 72 months vs. 54 months (p=0.029). Total LRR was 11% (8% vs. 17% in no RT group, p=0,349) and mean RFS of 95 months vs. 86 months (p=0.164). Significantly lower OS and DFS of the patients who were not treated with radiotherapy suggest that the indication for radiation treatment should be based on clinical pre-chemotherapy stage rather than pathological post-chemotherapy stage for non-inflammatory LABC.